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Heparin-induced thrombocytopenia is a serious complication
of heparin therapy that can lead to thromboembolism,
cardiovascular events, and death. Hemodialysis patients are
repeatedly exposed to heparin and are at risk for developing
antibodies to the platelet factor 4-heparin (PF4-H) complex.
We sought to determine the association between PF4-H
antibodies and mortality in a prospective cohort of 419
asymptomatic hemodialysis patients. Pre-dialysis blood
samples were screened for nonspecific PF4-H antibodies, and
all positive and indeterminate samples were subsequently
tested using immunoglobulin (Ig)G-specific PF4-H and
platelet serotonin-release assays. During a median follow-up
of 2.5 years there were 129 all-cause deaths. After controlling
for potential confounding variables, the relative risk of death
was significantly increased for patients with IgG-specific
PF4-H antibodies and further elevated with an indeterminate
serotonin-release assay. Our study suggests that IgG-specific
PF4-H antibody formation is associated with increased
mortality in hemodialysis patients.
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Heparin-induced thrombocytopenia is a serious complica-
tion of systemic heparin therapy. Exposure to heparin can
trigger an immune response resulting in the production of
antibodies against the platelet factor 4-heparin (PF4-H)
complex.1–3 Immunoglobulin (Ig)G PF4-H antibodies have
been associated with the development of both venous and
arterial thrombosis. Hemodialysis patients are repeatedly
exposed to heparin and are at risk for developing PF4-H
antibodies.
The morbidity and mortality of patients on chronic
hemodialysis continues to be substantial, primarily because
of vascular occlusive disease. Variables contributing to the
pathophysiology underlying this vasculopathy are not well
established.4,5 Antibodies to the PF4-H complex, without
clinical manifestations of heparin-induced thrombocytope-
nia, have been associated with both arterial and venous
thrombosis.6–14 In addition, PF4-H antibodies in asympto-
matic patients have been suggested as a possible cause of
increased morbidity and mortality in patients on main-
tenance hemodialysis.13,14 However, these studies were
limited by small sample sizes and important confounding
variables were not controlled for in the analyses. Accordingly,
the objective of this study was to examine the association
between PF4-H antibodies in asymptomatic patients and
survival in a large sample of hemodialysis patients while
simultaneously controlling for other potential risk factors of
mortality.
RESULTS
Of the 419 patients in this analysis, 35 (8.4%) had an
indeterminate result and 54 (12.9%) had a positive result
with the screening PF4-H ELISA assay. The IgG-specific
PF4-H ELISA assay was positive in 9 of 89 (10.1%) patients
with a positive or indeterminate screening PF4-H ELISA
result. One patient with indeterminate screening PF4-H
ELISA result had a positive IgG-specific PF4-H ELISA assay.
The serotonin release assay (SRA) screening assay was
positive in 5 of 89 (5.6%) patients with a positive PF4-H
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ELISA assay. Of these five subjects, all were indeterminate in
the full panel SRA testing. Four of these patients were positive
using the IgG-specific PF4-H antibody testing, while one
patient was negative for IgG-specific PF4-H antibody. No
patient had a positive full panel SRA.
The baseline characteristics of patients with nonspecific
PF4-H antibodies, IgG-specific PF4-H antibodies, and both
IgG-specific PF4-H antibodies and SRA indeterminate results
are depicted in Table 1 a–c. Patients with nonspecific PF4-H
antibodies were more likely to be black and diabetic (Table
1a). Patients with IgG-specific PF4-H antibodies or both IgG-
specific PF4-H antibodies and an indeterminate SRA were
also more likely to be black (Table 1b and c). Otherwise, the
patients with and without PF4-H antibodies had generally
similar baseline characteristics.
One hundred and twenty-nine (31%) patients died during
a median follow-up of 2.5 years. No patients were lost to
follow-up. Fourteen of 54 (26%) patients with nonspecific
PF4-H antibodies died during follow-up. In the group of
patients with IgG-specific PF4-H antibodies, 5/9 (56%) died
during follow-up. Three of five patients (60%) died of
cardiovascular complications (myocardial infarction, n¼ 2;
ischemic bowel, n¼ 1). Finally, 3/4 (75%) deaths occurred in
the group of patients with IgG-specific PF4-H antibodies and
indeterminate SRA result. Two of these patients died of
cardiovascular complications (myocardial infarction, n¼ 1;
ischemic bowel, n¼ 1).
We found a significant association between PF4-H
antibodies and mortality. For patients with IgG-specific
PF4-H antibodies, the risk of death was increased over two-
fold (unadjusted hazard ratio 2.40; 95% confidence interval
0.98–5.89; P¼ 0.06) (Table 2). After controlling for age;
gender; race; smoking status; diabetes; etiology of renal
failure; time on dialysis; history of malignancy; history of
angina, myocardial infarction, stroke, transient ischemic
attack, or peripheral vascular disease; hemoglobin; albumin;
urea reduction ratio; erythropoietin dose; and any thrombo-
philia, IgG-specific PF4-H antibodies were found to be an
independent predictor of mortality (adjusted hazard ratio
2.68; 95% confidence interval 1.08–6.63; P¼ 0.03) (Table 2).
An even greater risk of death was seen in patients with both
an IgG-specific PF4-H antibody and an indeterminate
serotonin-release assay (unadjusted hazard ratio 3.61; 95%
confidence interval 1.14–11.43; P¼ 0.02) (Table 2). After
controlling for the same variables listed above, the presence
of an IgG-specific PF4-H antibody and an indeterminate
Table 1a | Baseline characteristics of patients with nonspecific PF4-H antibodies, IgG-specific PF4-H antibodies, and both IgG-
specific PF4-H antibodies and indeterminate serotonin release assay
Nonspecific PF4-H antibodies
Characteristic Positive (n=54) Negative (n=365) P-value
Age, mean (s.d.), years 64.9 (15.8) 63.5 (16.5) 0.54
BMI, mean (s.d.), kg m2 25.7 (6.1) 25.6 (5.8) 0.88
Albumin, mean (s.d.), g l1 35.7 (4.7) 35.6 (4.1) 0.92
Time on dialysis, median (IQR), days 470.5 (225, 1332) 794 (348, 1533) 0.13
Hemoglobin, mean (s.d.), g dl1 11.6 (0.9) 11.8 (1.1) 0.48
Erythropoietin dose, mean (s.d.),
units per week
13 803 (10 243) 12 059 (8455) 0.24
Urea reduction ratio, mean (s.d.) 75.3 (7.6) 75.3 (6.4) 0.96
Never smoked, no. (%) 19 (35) 118 (32) 0.54
Male, no. (%) 28 (52) 233 (64) 0.09
Race, no. (%) 0.05
Caucasian 43 (80) 321 (88)
Black 7 (13) 17 (5)
Other 4 (7) 27 (7)
Etiology of renal failure, no. (%) 0.64
Diabetes 16 (30) 75 (21)
Glomerulonephritis 11 (20) 75 (21)
Hypertension 6 (11) 53 (15)
Polycystic kidney disease 3 (6) 31 (8)
Obstructive uropathy 1 (2) 21 (6)
Other 8 (15) 58 (15)
Unknown 9 (16) 52 (14)
Diabetes, no. (%) 25 (46) 110 (30) 0.02
Malignancy, no. (%) 10 (19) 64 (18) 0.86
DVT/PE, no. (%) 1 (2) 18 (5) 0.31
Peripheral vascular disease, no. (%) 10 (19) 114 (31) 0.06
Angina, no. (%) 18 (33) 108 (30) 0.58
Myocardial infarction, no. (%) 10 (19) 100 (27) 0.17
Cerebrovascular accident, no. (%) 8 (15) 29 (8) 0.09
Transient ischemic attack, no. (%) 1 (2) 19 (5) 0.28
BMI, body mass index; DVT, deep vein thrombosis; IgG, immunoglobulin G; IQR, interquartile range; PE, pulmonary embolism; PF4-H, platelet factor 4-heparin.
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serotonin-release assay remained a significant predictor of
mortality (adjusted hazard ratio 6.32; 95% confidence
interval 1.68–23.7; P¼ 0.01) (Table 2). The risk of death
was not significantly increased in patients with nonspecific
PF4-H antibodies (Table 2).
In the secondary analyses, we only found a significant
association between IgG-specific PF4-H antibodies and
minor cardiovascular event (Table 3). However, the point
estimates were similar and in the same direction as the hazard
ratios found for mortality.
DISCUSSION
To our knowledge, this is the largest and the most
comprehensive examination of the association between
PF4-H antibodies and survival in hemodialysis patients.
After adjusting for important variables, we found that the
presence of IgG-specific PF4-H antibodies was associated
with a significant increase in mortality for patients on
maintenance hemodialysis.
The hypercoagulable state of heparin-induced thrombo-
cytopenia is responsible for the marked increase in morbidity
and mortality seen with this condition. Venous and arterial
thrombotic events are common consequences.15 PF4-H
antibodies in asymptomatic patients have also been asso-
ciated with both arterial and venous thrombosis.6–14 Patients
on hemodialysis have a reduced survival compared to healthy
controls. Therefore, it makes biological sense that PF4-H
antibodies contribute to the pathophysiology underlying the
vasculopathy causing an increased mortality and morbidity
in patients on maintenance hemodialysis. Asymptomatic
patients on hemodialysis with a positive heparin-induced
platelet aggregation assay have been shown to have a 6.6-fold
increased mortality compared to controls.13 The mortality
was due to thromboembolic complications such as pulmon-
ary emboli and mesenteric ischemia.13 Patients on hemodia-
lysis with PF4-H antibodies in the highest tertile, but less
than that required for the serologic diagnosis of heparin-
induced thrombocytopenia, have also been shown to have an
increased rate of cardiovascular and all-cause mortality.14
Our results are consistent with previously published
literature13,14 and demonstrate an increase in all-cause
mortality for patients undergoing hemodialysis with IgG-
specific PF4-H antibodies suggesting an associative phenom-
enon. However, our study is not suited to suggest causality.
A majority of deaths in these subgroups were attributed
to cardiovascular events. Although previous research suggests
Table 1b | Baseline characteristics of patients with PF4-H antibodies, IgG-specific PF4-H antibodies, and both IgG-specific PF4-H
antibodies and indeterminate serotonin release assay
IgG-specific PF4-H antibodies
Characteristic Positive (n=9) Negative (n=410) P-value
Age, mean (s.d.), years 64.1 (19.0) 63.6 (16.3) 0.93
BMI, mean (s.d.), kg m2 24.4 (3.8) 25.7 (5.8) 0.53
Albumin, mean (s.d.), g l1 36.7 (4.5) 35.6 (4.2) 0.45
Time on dialysis, median (IQR), days 738 (330, 1398) 764 (317, 1514) 0.73
Hemoglobin, mean (s.d.), g dl1 12.1 (1.2) 11.7 (1.1) 0.31
Erythropoietin dose, mean (s.d.),
units per week
11 370 (8013) 12 304 (8735) 0.75
Urea reduction ratio, mean (s.d.) 74.9 (6.9) 75.3 (6.5) 0.88
Never smoked, no. (%) 2 (22) 135 (33) 0.79
Male, no. (%) 6 (67) 255 (62) 0.78
Race, no. (%) o0.001
Caucasian 5 (56) 359 (88)
Black 4 (44) 20 (5)
Other 0 31 (8)
Etiology of renal failure, no. (%) 0.83
Diabetes 3 (33) 88 (21)
Glomerulonephritis 1 (11) 85 (21)
Hypertension 1 (11) 58 (14)
Polycystic kidney disease 0 34 (8)
Obstructive uropathy 1 (11) 21 (5)
Other 1 (11) 65 (16)
Unknown 2 (22) 59 (14)
Diabetes, no. (%) 3 (33) 132 (32) 0.94
Malignancy, no. (%) 2 (22) 72 (18) 0.72
DVT/PE, no. (%) 0 19 (5) 0.51
Peripheral vascular disease, no. (%) 2 (22) 122 (30) 0.62
Angina, no. (%) 2 (22) 124 (30) 0.60
Myocardial infarction, no. (%) 2 (22) 108 (26) 0.78
Cerebrovascular accident, no. (%) 3 (33) 34 (8) 0.09
Transient ischemic attack, no. (%) 0 20 (5) 0.49
BMI, body mass index; DVT, deep vein thrombosis; IgG, immunoglobulin G; IQR, interquartile range; PE, pulmonary embolism; PF4-H, platelet factor 4-heparin.
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a link between the presence of PF4-H antibodies and
cardiovascular events,13,14 our results show only a trend
toward increased major cardiovascular events in patients with
PF4-H antibodies. Therefore, our observed mortality rates
cannot be completely explained by subclinical heparin-
induced thrombocytopenia and increased major cardiovas-
cular events. It is possible that our study was underpowered
to detect these secondary outcomes or that another
mechanism with elevated PF4-H antibodies remains to be
determined.
Whereas some suggest that cessation of heparin-like
products and use of other anticoagulants may be warranted
in patients with asymptomatic PF4-H antibodies on main-
tenance hemodialysis,13,16 others do not.17,18 Direct thrombin
inhibitors are an option for anticoagulation in hemodialysis
patients with heparin-induced thrombocytopenia. Case
reports and case series reporting the use of lepirudin for
patients with heparin-induced thrombocytopenia have
shown that this is a safe and effective alternative anti-
coagulation for hemodialysis.19,20 Argatroban, a direct
thrombin inhibitor, could also potentially be used.21,22 It
undergoes hepatic metabolism resulting in more predictable
serum level in patients on hemodialysis. Finally, another
alternative would be to use fondaparinox, a synthetic
pentasaccharide that selectively inhibits factor Xa. A case
Table 1c | Baseline characteristics of patients with PF4-H antibodies, IgG-specific PF4-H antibodies, and both IgG-specific PF4-H
antibodies and indeterminate serotonin release assay
IgG-specific PF4-H antibodies and indeterminate serotonin release assay
Characteristic Positive (n=4) Negative (n=415) P-value
Age, mean (s.d.), years 69.3 (14.4) 63.6 (16.4) 0.49
BMI, mean (s.d.), kg m2 24.7 (3.8) 25.6 (5.8) 0.76
Albumin, mean (s.d.), g l1 34.8 (5.6) 35.6 (4.2) 0.68
Time on dialysis, median (IQR), days 499 (144, 1068) 775 (319, 1533) 0.33
Hemoglobin, mean (s.d.), g dl1 12.2 (1.7) 11.7 (1.1) 0.45
Erythropoietin dose, mean (s.d.),
units per week
7917 (7026) 12 326 (8723) 0.31
Urea reduction ratio, mean (s.d.) 73.9 (8.2) 75.3 (6.5) 0.67
Never smoked, no. (%) 1 (25) 136 (33) 0.51
Male, no. (%) 3 (75) 258 (62) 0.60
Race, no. (%) 0.01
Caucasian 2 (50) 362 (87)
Black 2 (50) 22 (5)
Other 0 31 (8)
Etiology of renal failure, no. (%) 0.44
Diabetes 1 (25) 90 (22)
Glomerulonephritis 0 86 (21)
Hypertension 1 (25) 58 (14)
Polycystic kidney disease 0 34 (8)
Obstructive uropathy 0 22 (5)
Other 0 66 (16)
Unknown 2 (50) 59 (14)
Diabetes, no. (%) 1 (25) 134 (32) 0.76
Malignancy, no. (%) 2 (50) 72 (17) 0.09
DVT/PE, no. (%) 0 19 (5) 0.66
Peripheral vascular disease, no. (%) 0 124 (30) 0.19
Angina, no. (%) 0 126 (30) 0.19
Myocardial infarction, no. (%) 0 110 (27) 0.23
Cerebrovascular accident, no. (%) 1 (25) 36 (9) 0.25
Transient ischemic attack, no. (%) 0 20 (5) 0.65
BMI, body mass index; DVT, deep vein thrombosis; IgG, immunoglobulin G; IQR, interquartile range; PE, pulmonary embolism; PF4-H, platelet factor 4-heparin.
Table 2 | Cox regression analysis examining the risk of death
associated with PF4-H antibodies
Model Hazard ratio
95% Confidence
interval P-value
Nonspecific PF4-H antibodies
Univariate 0.87 0.50–1.52 0.64
Multivariatea 0.65 0.36–1.15 0.14
IgG-specific PF4-H antibodies
Univariate 2.40 0.98–5.89 0.06
Multivariatea 2.68 1.08–6.63 0.03
IgG-specific PF4-H antibodies and indeterminate serotonin release assay
Univariate 3.61 1.14–11.43 0.02
Multivariatea 6.32 1.68–23.7 0.01
IgG, immunoglobulin G; PF4-H, platelet factor 4-heparin.
aMultivariate models were controlled for age; gender; race; smoking status; diabetes;
etiology of renal failure; time on dialysis; history of malignancy; history of angina,
myocardial infarction, stroke, transient ischemic attack, or peripheral vascular
disease; hemoglobin; albumin; urea reduction ratio; erythropoietin dose; and any
thrombophilia.
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study recently reported the use of fondaparinox in a patient
treated for heparin-induced thrombocytopenia on hemodia-
lysis.23 However, it should be emphasized that these reports
are for patients with the clinical diagnosis heparin-induced
thrombocytopenia, not just for those with PF4-H antibodies.
Further studies will be needed to determine if modification of
anticoagulation with other agents would decrease the
prevalence of asymptomatic PF4-H antibodies and ultimately
lead to increased survival in this population.
It is important to note the limitations of this study. First,
PF4-H antibodies were only measured once and positive
titers were not repeated serially. The transient nature of PF4-
H antibodies has been shown in other patient populations.24
Therefore, it is possible that we underestimated the
prevalence of the PF4-H antibodies, which could explain
the absence of a statistically significant association between
PF4-H antibodies and major cardiovascular events in the
present analysis. However, no studies to date have demon-
strated such a transient nature of PF4-H antibodies in
patients who continue to be exposed to heparin.24 Platelet
counts were also measured only once. Platelet count is
unlikely to be a confounder, but a lower platelet count may
reflect those patients with more severe disease. Because the
platelet counts were not repeated serially, platelet nadir could
not be incorporated as a time-dependent covariate in the Cox
survival models. Second, ascertainment of cardiovascular
events was carried out by reviewing the medical record.
Therefore, it is possible that we underestimated the
prevalence of events if patients had an event not recorded
in our hospital record. Third, a form of selection bias may
have occurred as we chose our population from a group of
patients who survived progressive renal failure and were
currently on maintenance dialysis. We might have missed
enrolling patients with PF4-H antibodies who died before
study entry. Fourth, the PF4-H antibodies could represent a
nonspecific mediator of inflammation secondary to endothe-
lial dysfunction. Inflammation has been suggested to be a
significant contributor to cardiovascular disease in patients
with end-stage renal disease.25 Several different inflammatory
biomarkers (e.g., C-reactive protein) have been shown to
predict mortality. However, serum albumin level was similar
between the groups suggesting that inflammation is unlikely
the only pathological mechanism responsible for the
increased mortality. Finally, we cannot rule out an association
between PF4-H antibodies and cardiovascular events, as we
may have been underpowered to detect such an association
given that the number of events was relatively small.
In conclusion, IgG-specific PF4-H antibody formation is
associated with increased mortality for patients undergoing
maintenance hemodialysis. Further investigations are needed
in this population to determine if modification of antic-
oagulation with other agents would decrease the prevalence
of PF4-H antibodies and ultimately lead to increased survival
in this population.
MATERIALS AND METHODS
Patient population
Patients reported in this analysis were originally assembled for a
study evaluating thrombophillic disorders in dialysis.26 We also
investigated recently the association between PF4-H antibodies and
vascular access thrombosis using the same cohort of patients.27
Patients for the study were approached from three in-center and five
satellite units associated with The Ottawa Hospital, a Canadian
academic health science center that provides dialysis services in a
catchment area of one million. Inclusion criteria for the original
study26 included all adult (418 years of age) patients with a
functioning permanent dialysis access (arteriovenous fistula or graft)
Table 3 | Cox regression analysis examining the risk of cardiovascular events associated with PF4-H antibodies
Model Hazard ratio
95% Confidence
interval P-value
Nonspecific PF4-H antibodies
Major cardiovascular eventa 1.10 0.55–2.23 0.78
Multivariateb 0.91 0.44–1.85 0.79
Minor cardiovascular eventc 1.72 0.79–3.72 0.17
Multivariateb 1.77 0.82–3.84 0.15
IgG-specific PF4-H antibodies
Major cardiovascular eventa 1.71 0.42–6.99 0.46
Multivariateb 2.47 0.59–10.3 0.21
Minor cardiovascular eventc 2.87 0.69–11.9 0.15
Multivariateb 5.12 1.21–21.8 0.03
IgG-specific PF4-H antibodies and indeterminate serotonin release assay
Major cardiovascular eventa 1.76 0.24–12.7 0.58
Multivariateb 2.78 0.38–20.6 0.32
Minor cardiovascular eventc,d — — —
IgG, immunoglobulin G; PF4-H, platelet factor 4-heparin.
aMajor cardiovascular event was defined as myocardial infarction, cerebrovascular accident, pulmonary embolism, or deep vein thrombosis.
bMultivariate models were controlled for: age; gender; race; smoking status; diabetes; etiology of renal failure; time on dialysis; history of malignancy; history of angina,
myocardial infarction, stroke, transient ischemic attack or peripheral vascular disease; hemoglobin; albumin; urea reduction ratio; erythropoietin dose; any thrombophilia.
cMinor cardiovascular event was defined as transient ischemic attack or angina.
dThere were no events in the positive group.
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that provided written informed consent. Functioning access was
defined as successful cannulation with two needles and a minimum
blood flow of 250 ml min1 for at least one complete dialysis
treatment. Patients with a history of failed access (i.e., fistula or graft
created but never functioned as defined above) were eligible to
participate as long as they had one permanent access that at some
point functioned. All 419 patients in this analysis were receiving
maintenance, outpatient hemodialysis treatments. Patients received
a bolus of 1000–2000 units of unfractionated heparin (UFH) (Baxter
Canada, Mississauga, ON, Canada) at the start of each dialysis
treatment followed by a continuous infusion of approximately
1000 U h1. No patients received low molecular weight heparin for
chronic dialysis anticoagulation.
Laboratory tests
All participants had blood samples drawn pre-dialysis at the time of
inclusion into the study. All samples were tested for PF4-H
antibodies using an ELISA assay (GTI PF4 Enhanced, GTI
Diagnostics, Waukesha, WI, USA). PF4-H ELISA samples were
considered positive when the optical density (OD) measure was
above 0.4 absorbance units; indeterminate when the OD was
between 0.3 and 0.4; and negative when the OD was o0.3.
Indeterminate PF4-H ELISA samples were considered negative for
the statistical analysis. It was recently shown that the inclusion of the
high heparin confirmatory procedure in the commercial ELISA test
did not improve significantly the diagnostic specificity of the test in
a group of patients with asymptomatic antibodies.28,29 Therefore, a
confirmatory procedure with high dose of heparin was not
performed on the samples. PF4-H ELISA assays are detecting the
IgA/IgM and IgG PF4-H antibodies.30 However, not all antibodies
against PF4-H are pathogenic. IgG PF4-H antibodies have been
associated with the development of venous or arterial thrombosis.
Therefore, an IgG-specific PF4-H ELISA31,32 assay was performed on
all positive and indeterminate PF4-H ELISA samples as described
previously. The IgG-specific PF4-H ELISA assay was considered
positive if the sample had an OD above 0.45.
PF4-H ELISA assays are excellent for ruling out PF4-H
antibodies.30 Therefore, further testing with a platelet activation
test (e.g., platelet-SRA) is generally not required if the PF4-H ELISA
is negative. However, in patients with suspected heparin-induced
thrombocytopenia, a platelet activation test is more specific.30
Therefore an SRA33,34 was performed on all positive and
indeterminate PF4-H ELISA samples as described previously. A
pool of pre-screened donors was used for the SRA. All samples were
tested on two separate occasions. Each assay included a known
positive, negative, and weakly positive sample. Samples were
screened with the SRA at 0.1 and 0.3 U of UFH concentrations,
and at 0.1 U of low molecular weight heparin concentration
(Lovenox; Sanofi-Aventis, Paris, France). Any sample that had more
than 20% reactivity at any point underwent a full SRA assay with
concentrations of heparin including 0, 0.1, 0.3, and 100 U of UFH;
0.1 U of UFH with a monoclonal antibody (IV.3) added to block the
platelet Fc receptor, and 0.1 U of low molecular weight heparin. The
full SRA assay was considered positive if the sample had more than
20% serotonin release with 0.1, 0.3, and 0.1 U of low molecular
weight heparin, but less than 20% with 100 U UFH concentration or
0.1 U UFH with the monoclonal antibody. The SRA was considered
indeterminate if heparin-independent activation was observed (i.e.,
the test was not consistently negative or consistently positive with
added heparin and/or the high heparin did not inhibit reactivity
and/or the reactivity was not blocked by the antibody to the platelet
Fc receptor). Laboratory methods for the thrombophilia testing has
been described previously.26 The members of the laboratory staff
who performed the testing were not aware of the patient’s clinical
status.
Clinical end points
The primary end point of the study was all-cause mortality.
Ascertainment of death was determined by review of the medical
record. Death was categorized as cardiovascular if it was due to
myocardial infarction, stroke, congestive heart failure, or cardiac
arrest. Secondary end points included myocardial infarction, stroke,
deep vein thrombosis, pulmonary embolism, angina, and transient
ischemic attack. Myocardial infarction was defined as an increase in
troponin T above 0.1 mg l1 associated with documented chest
pain during a hospitalization. Stroke was defined when neurologic
deficits persisting beyond 24 h was associated with concordant
radiographic evidence of neural injury by computed tomography.
Transient ischemic attacks were diagnosed when a neurological
deficit resolved within 24 h with no associated radiographic
evidence of injury. Deep vein thrombosis was defined as evidence
of proximal thrombosis on venous compression ultrasonography.
Pulmonary embolism was diagnosed when there was a high
probability V/Q scan, a positive pulmonary angiogram, or spiral
CT demonstrating intraluminal filling defect in a vessel larger than a
segmental artery.
Statistical methods
Baseline dichotomous variables were compared with the w2-test and
continuous variables were compared with a t-test. The medians of
time on dialysis were compared using the Wilcoxon sign-rank test.
Cox proportional hazards regression was used to calculate
unadjusted and adjusted hazard ratios and their 95% confidence
intervals for the association between PF4-H antibodies and
mortality. In the primary analysis, patients were followed from
the time of study entry until death. Patients were censored at
the time of transplant or if still alive at study conclusion. The
following potentially confounding variables were included in the
multivariate models: age; gender; race; smoking status; diabetes; etiology
of renal failure; time on dialysis; history of malignancy; hemoglobin;
albumin; urea reduction ratio; erythropoietin dose; history of angina,
myocardial infarction, stroke, transient ischemic attack, or peripheral
vascular disease; and presence of any thrombophilia. Any thrombophilia
was defined previously26 as the presence of factor V Leiden,
prothrombin gene mutation or lupus anticoagulant, an elevated factor
VIII level (490th percentile), an elevated homocysteine concentration
(X85th percentile), an elevated lipoprotein (a) concentration (X85th
percentile), or an elevated anticardiolipin antibody (IgG or IgM)
concentration (430 GPL or MPL Uml1).
The models were constructed using a stepwise regression. Only
variables that reached statistical significance (Po0.05) for the
clinical end point were retained in the final model. In the
multivariate analysis, the proportionality assumption was not
violated. Analysis of the survival function vs survival time and of
the log (-log (survival)) vs log of the survival time resulted in
parallel curves. Simultaneous proportionality was also tested with
the PROC PHREG function using the SAS statistical software. In
secondary analyses, we examined the association between PF4-H
antibodies and specific vascular events. A major cardiovascular event
was defined as myocardial infarction, cerebrovascular accident,
pulmonary embolism, or deep vein thrombosis. A minor cardio-
vascular event was defined as a transient ischemic attack or angina.
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